Sterotherapeutics Launches Phase 2 Trial for Cushing’s Syndrome Drug
DOYLESTOWN, PA — Sterotherapeutics has initiated a Phase 2 clinical trial for ST-002, an innovative drug candidate aimed at treating Cushing’s Syndrome, a rare and severe endocrine disorder. The launch represents …
Sterotherapeutics Launches Phase 2 Trial for Cushing’s Syndrome Drug Read More